KalVista presents new data on Ekterly in Europe

KalVista (KALV) Pharmaceuticals announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY, the first and only oral on-demand treatment for hereditary angioedema, presented at the 20th German Allergy Congress in Dusseldorf, Germany from October 2-4, 2025. Across multiple ePoster presentations, EKTERLY demonstrated the ability to rapidly halt the progression of HAE attacks, deliver fast symptom relief and address key barriers associated with injectable therapies. Additional survey findings from German patients further highlight the urgent need for access to innovative on-demand HAE treatments across Europe. “The data presented at DGAKI underscore the transformative potential of EKTERLY for people living with HAE and highlight the urgent need for innovation across Europe,” said Paul Audhya, MD, MBA, Chief Medical Officer of KalVista. “As we’ve seen in the US, patients in Germany delay or avoid on-demand treatment due the challenges associated with injectable on-demand treatments, including injection-site reactions and the inability to readily access medication. An oral on-demand treatment has the ability to empower patients to better manage their condition, enabling earlier treatment of more attacks. With EKTERLY now approved in the European Union, we look forward to bringing this innovation to more people living with HAE-beginning with a launch in Germany this quarter followed by additional European launches in 2026 and beyond.”